<code id='95C081FF54'></code><style id='95C081FF54'></style>
    • <acronym id='95C081FF54'></acronym>
      <center id='95C081FF54'><center id='95C081FF54'><tfoot id='95C081FF54'></tfoot></center><abbr id='95C081FF54'><dir id='95C081FF54'><tfoot id='95C081FF54'></tfoot><noframes id='95C081FF54'>

    • <optgroup id='95C081FF54'><strike id='95C081FF54'><sup id='95C081FF54'></sup></strike><code id='95C081FF54'></code></optgroup>
        1. <b id='95C081FF54'><label id='95C081FF54'><select id='95C081FF54'><dt id='95C081FF54'><span id='95C081FF54'></span></dt></select></label></b><u id='95C081FF54'></u>
          <i id='95C081FF54'><strike id='95C081FF54'><tt id='95C081FF54'><pre id='95C081FF54'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:knowledge    Page View:73
          A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024
          Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

          Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

          Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

          advertisement

          The firm also said that it would be raising $500 million through a stock sale. 

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Malaria cases in Florida and Texas: Here’s what you need to know
          Malaria cases in Florida and Texas: Here’s what you need to know

          MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

          read more
          Special counsel informs Trump he is target in probe of efforts to overturn 2020 election
          Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

          5:16FormerPresidentandRepublicanpresidentialcandidateDonaldTrumptakesthestageduringtheTurningPointAc

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          Cassava Sciences’ Alzheimer’s clinical trials should be halted

          MollyFerguson/STATTheFoodandDrugAdministrationshouldhaltCassavaSciences’ongoingclinicaltrialsinAlzhe